Esperion Therapeutis.Inc. buy Global_Player
Summary
This prediction ended on 11.12.22 with a price of €4.76. The prediction for Esperion Therapeutis.Inc. disappointed with a performance of -26.62%. Global_Player has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Esperion Therapeutis.Inc. | -6.461% | -6.461% | 49.136% | -45.816% |
| iShares Core DAX® | -0,98 % | -4,72 % | 4,79 % | 53,02 % |
| iShares Nasdaq 100 | 1,16 % | 1,88 % | 20,23 % | 95,41 % |
| iShares Nikkei 225® | -1,59 % | -5,39 % | 31,35 % | 54,65 % |
| iShares S&P 500 | -0,28 % | 0,33 % | 13,91 % | 66,55 % |
According to Global_Player what are the pros and cons of Esperion Therapeutis.Inc. for the foreseeable future?
Pros
Cons
Comments by Global_Player for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.
Stopped prediction by Global_Player for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
29.08.25
29.08.26
15.09.25
Esperion Therapeutis.Inc.
26.02.25
26.02.26
01.03.25
Esperion Therapeutis.Inc.
25.04.24
25.04.25
27.04.24
Esperion Therapeutis.Inc.
28.08.23
28.08.24
30.08.23
Esperion Therapeutis.Inc.
26.07.21
26.07.22
08.08.21


